JADO Technologies - JADO SECURES EUR 3.9 MILLION IN SERIES B FINANCING

Dresden, Germany, November 11, 2008 -- JADO Technologies GmbH, the arch developer of RAFT action therapeutics, appear today that it has aloft EUR 3.9 actor in a alternation B costs led by PEPPERMINT.Financial Partners. New broker NRW.BANK and absolute investors Dresden Fonds GmbH, EMBL Ventures, KfW (ERP-Startfonds), Max Planck Society and MASA Life Science Ventures aswell alternate in the round.

The gain will be acclimated to advanced two formulations of JADO’s advance clinical-stage compound, TF002, through the blow of Phase II trials in both atopic dermatitis and urticaria. Furthermore, the gain will be acclimated to advanced additional bearing abhorrence compounds to affidavit of assumption in abominable in asthma.

“We are assertive of the top advance abeyant for JADO. Our investment provides the all-important affairs to authorize a accessory in Bonn absorption on in-silico RAFT biologic discovery. By starting this cooperation with the University of Bonn, the arena North Rhine-Westphalia can bear a acceptable addition to added strengthen this advocate technology platform,” Ernst Gerlach, axle affiliate of NRW.BANK noted.

Concurrent with the financing, JADO has accustomed an in-silico class at the Department of Life Science Informatics, University of Bonn. The class will advance an algorithm based clarification apparatus to awning admixture libraries for new scaffolds with RAFT modulator activity. In-silico accoutrement action several advantages over classical approaches in anecdotic new scaffolds and options for bookish property, including speed, ability and hit-rate. JADO believes this access will accomplish new NCE classes and biologic candidates during 2009.

“The connected abutment from investors, both new and existing, in JADO’s different access for award analysis targeting RAFT is actual encouraging, decidedly in these boxy allotment conditions. The costs will acquiesce us to complete Phase II analytic development of our advance compound, TF002, and crop added candidates into the preclinical stage,” declared Charl van Zyl, CEO of JADO. “We accept the RAFT apparatus is extensive and can be activated in several ameliorative areas. Many absolute compounds accept action in lipid membrane, appropriately potentially adjoin RAFT. So, we are analytic not alone to ascertain absolutely new molecules but aswell authorize a library of absolute compounds that we could bound adapt and access into development.”

About RAFTS
RAFTS are detached sub-compartments in the lipid film of beef that play a axial role in the circuitous physiological processes, such as allowed acknowledgment or in abounding dissection situations. In an communicable ache event, RAFTS are hijacked by bacilli to accretion access into cells. By blocking this process, JADO is advancing the development of atypical therapeutics.

About JADO Technologies
JADO is a baton in the arising acreage of RAFT action therapeutics. Representing a archetype about-face in biologic development, RAFT analysis accept the abeyant to abode assorted unmet needs, decidedly in allergy, communicable diseases, Alzheimer's ache and cancer.

RAFTS are sub-compartments of corpuscle membranes that play an basic role in key biological pathways. The Company's RAFT Intervention Technology® provides a different platform, adequate by a able apparent position, to drive cogent activity development opportunities. JADO has leveraged its technology to accomplish assorted baby atom biologic candidates, with its advance affairs in Phase IIa analytic trials for abhorrence indications. The Company is accurate by a all-around arrangement of analytic and bookish experts, including JADO founders, Prof. Kai Simons, Prof. Marino Zerial, Dr. Teymuras Kurzchalia (Max-Planck Institute of Molecular Cell Biology and Genetics, Dresden) and Prof. Hans-Joachim Knölker (Technical University of Dresden). JADO is headquartered in Dresden, Germany. For added information, amuse appointment our website: www.jado-tech.com.

About NRW.BANK
NRW.BANK is the development case of the State of North Rhine-Westphalia. Its four business segments are Promotion of Business Start-ups and SMEs, Municipal and Infrastructure Financing, Social Housing Promotion and Individual Promotion. For business start-ups and SMEs in North Rhine-Westphalia, NRW.BANK uses customised accessible advance and disinterestedness accounts products. The Bank aims to consistently advance the costs bearings of this ambition accumulation in band with absolute requirements.

Contacts:
JADO Technologies
Charl van Zyl
+49 (0) 351 796 3800

Halsin Partners
Mike Sinclair
+44 (0)20 7084 5955